Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Hauschild A, Garbe C, Ascierto P, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea A, Gebhardt C, Gershenwald J, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood J, Lebbé C, Long G, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak V, Wainstein A, Weichenthal M, Nuti P
LANCET ONCOL. 2025;26(1):12-14.

Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
Kött J, Zell T, Zimmermann N, Rünger A, Smit D, Abeck F, Geidel G, Hansen-Abeck I, Heidrich I, Weichenthal M, Ugurel S, Leiter U, Berking C, Gutzmer R, Schadendorf D, Zimmer L, Livingstone E, Wasielewski I, Mohr P, Meier F, Haferkamp S, Drexler K, Herbst R, Kellner I, Utikal J, Wohlfeil S, Pföhler C, Adam L, Meiss F, Möbes M, Welzel J, Schilling B, Ziller F, Kaatz M, Kreuter A, Sindrilaru A, Dippel E, Sachse M, Weishaupt C, Hüning S, Heinzerling L, Loquai C, Bauer A, Schneider S, Gebhardt C
EUR J CANCER. 2025;214:115159.

Evaluation of S100A8/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition
Melzer Y, Fergen N, Mess C, Stadler J, Geidel G, Schwietzer Y, Kött J, Pantel K, Schneider S, Utikal J, Wladykowski E, Vidal-Y-Sy S, Bauer A, Gebhardt C
TRANSL ONCOL. 2025;52:102224.

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study: Addendum
Bai X, Shaheen A, Grieco C, d'Arienzo P, Mina F, Czapla J, Lawless A, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park B, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto P, Johnson D, Lo S, Long G, Menzies A, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar Y, Haydon A, Quaglino P, Boland G, Sullivan R, Furness A, Plummer R, Flaherty K
ECLINICALMEDICINE. 2024;71:102564.

Through the patients' eyes: psychometric evaluation of the 64-item version of the Experienced Patient-Centeredness Questionnaire (EPAT-64)
Christalle E, Zeh S, Führes H, Hahlweg P, Zill J, Härter M, Bokemeyer C, Gallinat J, Gebhardt C, Magnussen C, Müller V, Schmalstieg-Bahr K, Strahl A, Kriston L, Scholl I
BMJ QUAL SAF. 2024 [Epub ahead of print].

Age matters: Rethinking SLNB's reliability in melanoma mortality prediction
Gebhardt C
J EUR ACAD DERMATOL. 2024;38(4):639-640.

Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma
Geidel G, Abeck F, Hansen I, Kött J, Heidrich I, Rünger A, Hildebrandt L, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(6):e473-e475.

Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma
Geidel G, Parnian N, Meß C, Schlepper N, Rünger A, Heidrich I, Hansen I, Smit D, Menz A, Pantel K, Schneider S, Kött J, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(10):2017-2023.

Erfolgreiche Behandlung eines Checkpoint‐Inhibitor‐assoziierten bullösen Pemphigoids mit Dupilumab bei Angiosarkom
Hansen I, Gebhardt C, Booken N, Schneider S
J DTSCH DERMATOL GES. 2024;22(4):587-590.

Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma
Hansen I, Gebhardt C, Booken N, Schneider S
J DTSCH DERMATOL GES. 2024;22(4):587-589.

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
Hansen I, Kött J, Heidenreich S, Ayuk F, Doll P, Abeck F, Booken N, Gebhardt C, Schneider S
Journal of the European Academy of Dermatology and Venerology Clinical Practice. 2024;3(1):317-320.

Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma
Hansen I, Rünger A, Noebel C, Geidel G, Kött J, Menz A, Hildebrandt L, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(9):e820-e822.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy
Kött J, Hoehne I, Heidrich I, Zimmermann N, Reese K, Zell T, Geidel G, Rünger A, Schneider S, Pantel K, Smit D, Gebhardt C
CANCERS. 2024;16(9):.

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma
Kött J, Zimmermann N, Zell T, Heidrich I, Geidel G, Rünger A, Smit D, Merkle M, Parnian N, Hansen I, Hoehne I, Abeck F, Torster L, Weichenthal M, Pantel K, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(8):1575–1587.

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit D, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, Gebhardt C
EUR J CANCER. 2024;202:.

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma
Sementsov M, Ott L, Kött J, Sartori A, Lusque A, Degenhardt S, Segier B, Heidrich I, Volkmer B, Greinert R, Mohr P, Simon R, Stadler J, Irwin D, Koch C, Andreas A, Deitert B, Thewes V, Trumpp A, Schneeweiss A, Belloum Y, Peine S, Wikman H, Riethdorf S, Schneider S, Gebhardt C, Pantel K, Keller L
EMBO MOL MED. 2024;16(7):1560-1578.

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Wohlfeil S, Kranzmann L, Weiß C, von Wasielewski I, Klespe K, Kähler K, Weichenthal M, Schadendorf D, Zimmer L, Mohr P, Meier F, Pfoehler C, Berking C, Heppt M, Herbst R, Kreuter A, Gutzmer R, Ulrich J, Meiss F, Gebhardt C, Dippel E, Leiter U, Schilling B, Ugurel S, Utikal J
INT J CANCER. 2024;155(10):1808-1823.

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
Bai X, Shaheen A, Grieco C, d'Arienzo P, Mina F, Czapla J, Lawless A, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park B, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto P, Johnson D, Lo S, Long G, Menzies A, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar Y, Haydon A, Quaglino P, Boland G, Sullivan R, Furness A, Plummer R, Flaherty K
ECLINICALMEDICINE. 2023;65:102290.

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel J, Weyandt G, Trommer M, Lodde G, Placke J, Zimmer L, Livingstone E, Becker J, Horn S, Schadendorf D, Ugurel S
J IMMUNOTHER CANCER. 2023;11(4):.

Status quo und Zukunftsperspektiven der molekularen Diagnostik in der Dermatologie
Gebhardt C, Eyerich K, Garzorz-Stark N
J DTSCH DERMATOL GES. 2023;21(4):415-418.

Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma
Geidel G, Adam L, Rünger A, Menz A, Kött J, Haalck T, Gebhardt C
J EUR ACAD DERMATOL. 2023;37(12):e1414-e1416.

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe K, Meier F, Mohr P, Kähler K, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel J, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt M, Kiecker F, Haferkamp S, Gebhardt C, Simon J, Grabbe S, Loquai C
J IMMUNOTHER CANCER. 2023;11(9):.

Successful Treatment of PD-1 Inhibitor-induced Psoriasis with Infliximab
Hansen I, Heidrich I, Abeck F, Kött J, Booken N, Gebhardt C, Schneider S
J EUR ACAD DERMATOL. 2023;37(5):e621-e623.

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
Hassel J, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, Siveke J, Hauschild A, Schadendorf D
EUR J CANCER. 2023;191:112986.

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
Stadler J, Keller L, Mess C, Bauer A, Koett J, Geidel G, Heidrich I, Vidal-Y-Sy S, Andreas A, Stramaglia C, Sementsov M, Haberstroh W, Deitert B, Hoehne I, Reschke R, Haalck T, Pantel K, Gebhardt C, Schneider S
J IMMUNOTHER CANCER. 2023;11(5):.

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, Forschner A, Leiter U, Ulrich J, Utikal J, Welzel J, Kaatz M, Gebhardt C, Herbst R, Sindrilaru A, Dippel E, Sachse M, Meiss F, Heinzerling L, Haferkamp S, Weishaupt C, Löffler H, Kreft S, Griewank K, Livingstone E, Schadendorf D, Ugurel S, Zimmer L
EUR J CANCER. 2023;188:140-151.

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
Ammann N, Schwietzer Y, Mess C, Stadler J, Geidel G, Kött J, Pantel K, Schneider S, Utikal J, Bauer A, Gebhardt C
CANCERS. 2022;14(22):.

Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Bauer A, Gorzelanny C, Gebhardt C, Pantel K, Schneider S
CANCER TREAT REV. 2022;102:.

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients
DeTemple V, Hassel J, Sachse M, Grimmelmann I, Leiter U, Gebhardt C, Eckardt J, Pföhler C, Angela Y, Hübbe H, Gutzmer R
CANCERS. 2022;14(21):.

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
Geidel G, Heidrich I, Kött J, Schneider S, Pantel K, Gebhardt C
NPJ PRECIS ONCOL. 2022;6(1):.

Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report
Geidel G, Rünger A, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2022;36(S1):49-52.

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Glutsch V, Schummer P, Kneitz H, Gesierich A, Goebeler M, Klein D, Posch C, Gebhardt C, Haferkamp S, Zimmer L, Becker J, Leiter U, Weichenthal M, Schadendorf D, Ugurel S, Schilling B
J IMMUNOTHER CANCER. 2022;10(11):.

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
Haist M, Stege H, Lang B, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, Ugurel S, Placke J, Weichenthal M, Gutzmer R, Leiter U, Kaatz M, Haferkamp S, Berking C, Heppt M, Tschechne B, Schummer P, Gebhardt C, Grabbe S, Loquai C
CANCERS. 2022;14(22):.

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives
Heppt M, Gebhardt C, Hassel J, Alter M, Gutzmer R, Leiter U, Berking C
CANCERS. 2022;14(19):.

Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels
Liu X, Wang Y, Bauer A, Kirschfink M, Ding P, Gebhardt C, Borsig L, Tüting T, Renné T, Häffner K, Hu W, Schneider S, Gorzelanny C
P NATL ACAD SCI USA. 2022;119(33):.

Immune checkpoint blockade for organ-transplant recipients with cancer: A review
Rünger A, Schadendorf D, Hauschild A, Gebhardt C
EUR J CANCER. 2022;175:326-335.

Current and future clinical applications of ctDNA in immuno-oncology
Stadler J, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, Keller L, Pantel K
CANCER RES. 2022;82(3):349-358.

Meeting Report: 47th Annual Meeting of the "Arbeitsgemeinschaft Dermatologische Forschung"
Stary G, Fabri M, Gebhardt C, Eming R, Matthias J, Vorobyev A, Effern M, Strobl J, Günther C, Zielinski C, Dudziak D, Géraud C, Raker V, Butze M, Zhao F, Wang Y, Gerloff D, Bertschi N, Gaffal E, Buhl T
EXP DERMATOL. 2022;31(10):1641-1651.

Molecular diagnostics in dermatology
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N
J DTSCH DERMATOL GES. 2022;20(3):287-295.

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care - a Randomized Pilot Study
Ullrich A, Wilde S, Müller V, Sinn M, Gebhardt C, Velthaus J, Gerlach C, Bokemeyer C, Oechsle K
ONCOL RES TREAT. 2022;45(3):118-129.

Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III
Ammann N, Geidel G, Schneider S, Gebhardt C
J DTSCH DERMATOL GES. 2021;19(9):1341-1345.

Adjuvant pembrolizumab-related hyperprogression in stage III melanoma
Ammann N, Geidel G, Schneider S, Gebhardt C
J DTSCH DERMATOL GES. 2021;19(9):1341-1345.

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East
Ascierto P, Orlova K, Grignani G, Dudzisz-Śledź M, Fenig E, Chiarion Sileni V, Fazio N, Samimi M, Mortier L, Gebhardt C, Kramkimel N, Steven N, Bechter O, Arance A, Benincasa E, Kostkova L, Costa N, Lorigan P
INT J CANCER. 2021;149(11):1926-1934.

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen C, Kött J, Hartung T, Torster L, Gebhardt C
CANCERS. 2021;13(24):.

47. Jahrestagung der „Arbeitsgemeinschaft Dermatologische Forschung“ (ADF)
Gaffal E, Eming R, Fabri M, Gebhardt C, Stary G, Buhl T
J DTSCH DERMATOL GES. 2021;19(8):1253-1254.

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study
Gebhardt C, Simon S, Weber R, Gries M, Mun D, Reinhard R, Holland-Letz T, Umansky V, Utikal J
CELL IMMUNOL. 2021;360:104274.

Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant
Geidel G, Ammann N, Schneider S, Gebhardt C
J DTSCH DERMATOL GES. 2021;19(S1):37-39.

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
Lodde G, Forschner A, Hassel J, Wulfken L, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E
CANCERS. 2021;13(10):.

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse S, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider S, Belczacka I, Volkmer B, Greinert R, Yaspo M, Harter P, Pantel K, Wikman H
INT J MOL SCI. 2021;22(13):.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan P, Hassel J, Rutkowski P, Baurain J, Butler M, Schlaak M, Sullivan R, Ochsenreither S, Dummer R, Kirkwood J, Joshua A, Sacco J, Shoushtari A, Orloff M, Piulats J, Milhem M, Salama A, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal R, Hamid O, Abdullah S, Holland C, Goodall H, Piperno-Neumann S
NEW ENGL J MED. 2021;385(13):1196-1206.

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, Enk A, Gebhardt C, Gesierich A, Goebeler M, Goerdt S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel J, Heinzerling L, Kähler K, Kaume K, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, Löffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz R, Maul L, Müller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pföhler C, Posch C, Richtig E, Rompel R, Sachse M, Sauder S, Schadendorf D, Schatton K, Schulze H, Schultz E, Schilling B, Schmuth M, Simon J, Streit M, Terheyden P, Thiem A, Tüting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt M
J CANCER RES CLIN. 2021;147(6):1763-1771.

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler T
J IMMUNOTHER CANCER. 2021;9(5):.

Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group
Wessely A, Steeb T, Berking C, Schlaak M, Heppt M
EUR J CANCER. 2021;143:43-45.

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions
Gebhardt C, Ascierto P, Atkinson V, Corrie P, Dummer R, Schadendorf D
EUR J CANCER. 2020;138:68-76.

Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients
Schneegans S, Lück L, Besler K, Bluhm L, Stadler J, Staub J, Greinert R, Volkmer B, Kubista M, Gebhardt C, Sartori A, Irwin D, Serkkola E, Af Hällström T, Lianidou E, Sprenger-Haussels M, Hussong M, Mohr P, Schneider S, Shaffer J, Pantel K, Wikman H
MOL ONCOL. 2020;14(5):1001-1015.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task
Brinker T, Hekler A, Enk A, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal J, von Kalle C
EUR J CANCER. 2019;113:47-54.

46th annual congress of the "Arbeitsgemeinschaft Dermatologische Forschung" in Munich, Germany
Gaffal E, Eming R, Fabri M, Gebhardt C, Stary G, Eyerich S, Hölzel M, Kosnopfel C, Neubert E, Rauer D, Rodríguez E, Thiem A, von Meyenn L, Buhl T
EXP DERMATOL. 2019;28(9):1094-1099.

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis
Jäger K, Larribère L, Wu H, Weiss C, Gebhardt C, Utikal J
CANCERS. 2019;11(1):.

Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target
Orouji E, Federico A, Larribère L, Novak D, Lipka D, Assenov Y, Sachindra S, Hüser L, Granados K, Gebhardt C, Plass C, Umansky V, Utikal J
INT J CANCER. 2019;145(12):3462-3477.

Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance - the impact of immunosuppression on frequency of cSCC.
Plasmeijer E, Sachse M, Gebhardt C, Geusau A, Bouwes B
J EUR ACAD DERMATOL. 2019;33(58):33-37.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Schilling B, Martens A, Geukes Foppen M, Gebhardt C, Hassel J, Rozeman E, Gesierich A, Gutzmer R, Kähler K, Livingstone E, Diamantopoulos P, Gogas H, Madonna G, Ascierto P, Goldinger S, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B
CANCER IMMUNOL IMMUN. 2019;68(5):765-772.

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Wagner N, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Gebhardt C
J IMMUNOTHER CANCER. 2019;2019(7):.

Extracorporal Shock Wave Therapy Enhances Receptor for Advanced Glycated End-Product-Dependent Flap Survival and Angiogenesis
Birgin E, Gebhardt C, Hetjens S, Fischer S, Rückert F, Reichenberger M
ANN PLAS SURG. 2018;80(4):424-431.

CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze T, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V
CANCER RES. 2018;78(1):157-167.

Liquid biopsy to monitor melanoma patients
Gaiser M, von Bubnoff N, Gebhardt C, Utikal J
J DTSCH DERMATOL GES. 2018;16(4):405-414.

Liquid Biopsy zur Überwachung von Melanompatienten
Gaiser M, von Bubnoff N, Gebhardt C, Utikal J
J DTSCH DERMATOL GES. 2018;16(4):405-416.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy
Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M
CLIN CHEM. 2018;64(5):830-842.

45th meeting of the Arbeitsgemeinschaft Dermatologische Forschung
Loser K, Eming R, Eyerich K, Gebhardt C, Ludwig R, Baghin V, Baurecht H, Forsthuber A, Glodde N, Schmidt E, Schmidt T, Shridhar N, Simon B, Gaffal E
EXP DERMATOL. 2018;27(7):798-802.

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α
Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel J
MELANOMA RES. 2018;28(3):204-210.

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
Reinhard R, Gebhardt C, Maurier N, Larribère L, Orouji A, Utikal J
JAAD case reports. 2018;4(2):129-131.

Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas
Baum C, Weiss C, Gebhardt C, Utikal J, Marx A, Koenen W, Géraud C
INT J CANCER. 2017;140(8):1907-1917.

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
Bernhardt M, Novak D, Assenov Y, Orouji E, Knappe N, Weina K, Reith M, Larribere L, Gebhardt C, Plass C, Umansky V, Utikal J
STEM CELL REP. 2017;8(5):1379-1391.

D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress
Desch A, Gebhardt C, Utikal J, Schneider S
INT J CANCER. 2017;140(4):914-921.

The shedded ectodomain of Lyve-1 expressed on M2-like tumorassociated macrophages inhibits melanoma cell proliferation
Dollt C, Becker K, Michel J, Melchers S, Weis C, Schledzewski K, Krewer A, Kloss L, Gebhardt C, Utikal J, Schmieder A
ONCOTARGET. 2017;8(61):103682-103692.

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, Scolyer R, Long G, Janzen V, Teng M, Kastenmüller W, Mazzone M, Smyth M, Tüting T, Hölzel M
IMMUNITY. 2017;47(4):789-802.e9.

Role of mutational status of GNAQ and GNA11 in the diagnosis of melanocytic tumors: Response
Griewank K, Koelsche C, Wenz F, Giordano F, Gebhardt C
J NEUROSURG. 2017.

Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair
Kumar V, Fleming T, Terjung S, Gorzelanny C, Gebhardt C, Agrawal R, Mall M, Ranzinger J, Zeier M, Madhusudhan T, Ranjan S, Isermann B, Liesz A, Deshpande D, Häring H, Biswas S, Reynolds P, Hammes H, Peperkok R, Angel P, Herzig S, Nawroth P
NUCLEIC ACIDS RES. 2017;45(18):10595-10613.

Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors
Reinhard R, Gebhardt C, Schmieder A, Umansky V, Utikal J
J EUR ACAD DERMATOL. 2017;31(8):e375-e377.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin U, Derhovanessian E, Miller M, Kloke B, Simon P, Löwer M, Bukur V, Tadmor A, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn A, Buck J, Heesch S, Schreeb K, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück A, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö
NATURE. 2017;547(7662):222-226.

Myeloid-derived suppressor cells and tumor escape from immune surveillance
Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J
SEMIN IMMUNOPATHOL. 2017;39(3):295-305.

CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma
Umansky V, Blattner C, Gebhardt C, Utikal J
CANCER IMMUNOL IMMUN. 2017;66(8):1015-1023.

Endothelial Notch1 Activity Facilitates Metastasis
Wieland E, Rodriguez-Vita J, Liebler S, Mogler C, Moll I, Herberich S, Espinet E, Herpel E, Menuchin A, Chang-Claude J, Hoffmeister M, Gebhardt C, Brenner H, Trumpp A, Siebel C, Hecker M, Utikal J, Sprinzak D, Fischer A
CANCER CELL. 2017;31(3):355-367.

Neural crest-like gene FOXD1 plays a role in melanoma cell migration and invasion
Gebhardt C
2016.

Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients
Gebhardt C, Lichtenberger R, Utikal J
J DTSCH DERMATOL GES. 2016;14(2):158-64.

The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman
Hoffmann M, Koelsche C, Seiz-Rosenhagen M, Mai S, Lohr F, Reuss D, Wenz F, Gebhardt C, Giordano F
J NEUROSURG. 2016;125(1):53-56.

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages
Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque M, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, Dummer R, Contassot E, French L
SCI REP-UK. 2016;6:29914.

Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells
Knappe N, Novak D, Weina K, Bernhardt M, Reith M, Larribere L, Hölzel M, Tüting T, Gebhardt C, Umansky V, Utikal J
STEM CELLS. 2016;34(4):832-46.

MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma
Orouji E, Orouji A, Gaiser T, Larribère L, Gebhardt C, Utikal J
INT J CANCER. 2016;138(9):2257-62.

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky V, Blattner C, Gebhardt C, Utikal J
VACCINES-BASEL. 2016;4(4):.

Predictive immune markers in advanced melanoma patients treated with ipilimumab
Umansky V, Utikal J, Gebhardt C
ONCOIMMUNOLOGY. 2016;5(6):e1158901.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide B, Martens A, Hassel J, Berking C, Postow M, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo A, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto P, Hospers G, Garbe C, Wolchok J
CLIN CANCER RES. 2016;22(22):5487-5496.

TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cells
Weina K, Wu H, Knappe N, Orouji E, Novak D, Bernhardt M, Hüser L, Larribère L, Umansky V, Gebhardt C, Utikal J
PIGM CELL MELANOMA R. 2016;29(4):453-458.

An unusual case with multiple epidermotropic melanoma metastases developing under combination therapy with dabrafenib and trametinib
Gebhardt C
J DTSCH DERMATOL GES. 2015.

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V
CLIN CANCER RES. 2015;21(24):5453-9.

Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib
Gebhardt C, Staub J, Schmieder A, Goerdt S, Utikal J
ACTA DERM-VENEREOL. 2015;95(1):96-7.

Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy
Gebhardt C, Ziegler B, Stadler S, Goerdt S, Utikal J
BRIT J DERMATOL. 2015;172(4):1156-8.

Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients
Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze T, Utikal J, Umansky V
INT J CANCER. 2015;136(10):2352-60.

T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response
Pfirschke C, Gebhardt C, Zörnig I, Pritsch M, Eichmüller S, Jäger D, Enk A, Beckhove P
CANCER IMMUNOL IMMUN. 2015;64(11):1369-81.

New therapeutic options for advanced non-resectable malignant melanoma
Stadler S, Weina K, Gebhardt C, Utikal J
ADV MED SCI-POLAND. 2015;60(1):83-8.

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Wagner N, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C
INT J CANCER. 2015;137(11):2607-17.

Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter
Bernhardt M, Orouji E, Larribere L, Gebhardt C, Utikal J
CLIN CANCER RES. 2014;20(9):2498-9.

Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report
Orouji E, Ziegler B, Umansky V, Gebhardt C, Utikal J
MEDICINE. 2014;93(28):e161.

Myeloid-derived suppressor cells in malignant melanoma
Umansky V, Sevko A, Gebhardt C, Utikal J
J DTSCH DERMATOL GES. 2014;12(11):1021-7.

Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation
Riehl A, Bauer T, Brors B, Busch H, Mark R, Németh J, Gebhardt C, Bierhaus A, Nawroth P, Eils R, König R, Angel P, Hess J
BMC GENOMICS. 2010;11:537.

Standards and Trends in the Treatment of Malignant Melanoma
Gebhardt C, Näher H
Onkopipeline. 2009;2:101-113.

S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis
Németh J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J
HEPATOLOGY. 2009;50(4):1251-62.

RAGE signaling sustains inflammation and promotes tumor development
Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth P, Hess J, Angel P
J EXP MED. 2008;205(2):275-85.

S100A8 and S100A9 in inflammation and cancer
Gebhardt C, Németh J, Angel P, Hess J
BIOCHEM PHARMACOL. 2006;72(11):1622-31.

A novel aspartic proteinase-like gene expressed in stratified epithelia and squamous cell carcinoma of the skin
Rhiemeier V, Breitenbach U, Richter K, Gebhardt C, Vogt I, Hartenstein B, Fürstenberger G, Mauch C, Hess J, Angel P
AM J PATHOL. 2006;168(4):1354-64.

c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis
Gebhardt C, Breitenbach U, Richter K, Fürstenberger G, Mauch C, Angel P, Hess J
AM J PATHOL. 2005;167(1):243-53.

Myeloid cell function in MRP-14 (S100A9) null mice
Hobbs J, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson M, Hogg N
MOL CELL BIOL. 2003;23(7):2564-76.

Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells
Schlingemann J, Hess J, Wrobel G, Breitenbach U, Gebhardt C, Steinlein P, Kramer H, Fürstenberger G, Hahn M, Angel P, Lichter P
INT J CANCER. 2003;104(6):699-708.

Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis
Gebhardt C, Breitenbach U, Tuckermann J, Dittrich B, Richter K, Angel P
ONCOGENE. 2002;21(27):4266-76.

Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis
Breitenbach U, Tuckermann J, Gebhardt C, Richter K, Fürstenberger G, Christofori G, Angel P
J INVEST DERMATOL. 2001;117(3):634-40.

Letzte Aktualisierung aus dem FIS: 09.05.2025 - 00:34 Uhr